Mereo BioPharma Group plc (MREO)
Largest Insider Buys in Sector
MREO Stock Price History Chart
MREO Stock Performance
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 …
Insider Activity of Mereo BioPharma Group plc
Over the last 12 months, insiders at Mereo BioPharma Group plc have bought $0 and sold $3.08M worth of Mereo BioPharma Group plc stock.
On average, over the past 5 years, insiders at Mereo BioPharma Group plc have bought $0 and sold $3.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Mereo BioPharma Group plc
| 2024-09-13 | Sale | Chief Executive Officer | 60,046 0.0454% | $4.22 | $253,454 | -4.21% | ||
| 2024-09-13 | Sale | General Counsel | 20,946 0.0158% | $4.22 | $88,413 | -4.21% | ||
| 2024-09-13 | Sale | Chief Financial Officer | 19,158 0.0145% | $4.22 | $80,866 | -4.21% | ||
| 2024-09-13 | Sale | Chief Scientific Officer | 10,937 0.0083% | $4.22 | $46,165 | -4.21% | ||
| 2024-09-13 | Sale | See Remarks | 100,312 0.0759% | $4.22 | $423,417 | -4.21% | ||
| 2024-09-12 | Sale | Chief Executive Officer | 28,611 0.0229% | $4.47 | $127,968 | -6.61% | ||
| 2024-09-12 | Sale | General Counsel | 9,980 0.008% | $4.47 | $44,638 | -6.61% | ||
| 2024-09-12 | Sale | See Remarks | 47,798 0.0383% | $4.47 | $213,786 | -6.61% | ||
| 2024-09-12 | Sale | Chief Financial Officer | 9,128 0.0073% | $4.47 | $40,827 | -6.61% | ||
| 2024-09-12 | Sale | Chief Scientific Officer | 5,212 0.0042% | $4.47 | $23,312 | -6.61% | ||
| 2024-08-22 | Sale | director | 105,244 0.0836% | $4.43 | $466,210 | -7.21% | ||
| 2024-06-26 | Sale | Chief Executive Officer | 92,273 0.0561% | $3.39 | $313,101 | +17.34% | ||
| 2024-06-26 | Sale | General Counsel | 32,187 0.0196% | $3.39 | $109,217 | +17.34% | ||
| 2024-06-26 | Sale | Chief Financial Officer | 29,439 0.0179% | $3.39 | $99,892 | +17.34% | ||
| 2024-06-26 | Sale | Chief Scientific Officer | 16,808 0.0102% | $3.39 | $57,033 | +17.34% | ||
| 2024-06-26 | Sale | See Remarks | 22,968 0.014% | $3.39 | $77,935 | +17.34% | ||
| 2024-06-25 | Sale | Chief Executive Officer | 40,712 0.027% | $3.69 | $150,386 | +16.86% | ||
| 2024-06-25 | Sale | General Counsel | 14,202 0.0094% | $3.69 | $52,461 | +16.86% | ||
| 2024-06-25 | Sale | Chief Financial Officer | 12,990 0.0086% | $3.69 | $47,984 | +16.86% | ||
| 2024-06-25 | Sale | Chief Scientific Officer | 7,416 0.0049% | $3.69 | $27,394 | +16.86% |